PETRI DISH PERSPECTIVES
Burma | Chicago
Scientist 🥼🧪🔬
Covering biotech, pharma, and healthcare companies shaping the world 🧬🏥🌎
Stream new episodes every THURSDAY!
https://linktr.ee/maneadkhin
#biotech #pharma #healthcare #podcast #petridishperspectives
Episodes
61 episodes
Episode 55: Alnylam
From the discovery of RNA interference to the first FDA-approved gene-silencing therapy, this week on Petri Dish Perspectives, we dive into the story of Alnylam Pharmaceuticals, the company that turned one of biology’s most powerful me...
Episode 54: All about 340B
In this episode of Petri Dish Perspectives, we break down the 340B Drug Pricing Program, a little-known but massively influential policy shaping how hospitals, pharmacies, and drug manufacturers operate today. Created under the ...
April 2026: Biotech & Pharma NEWS Roundup
Welcome to your essential overview of the global biotech and pharmaceutical landscape for April 2026!This month was dominated by a high-stakes pivot toward oral obesity treatments, a massive consolidation of precision oncology platforms ...
Episode 53: CAR-T Therapies
What if cancer treatment wasn’t a drug but a living, evolving system inside your body?In this episode, we break down one of the most revolutionary innovations in modern medicine: CAR-T cell therapy. From its origins in academic la...
Episode 52: Daiichi Sankyo
In this episode of Petri Dish Perspectives: Biotech Unleashed, we break down the rise of Daiichi Sankyo, a company that quietly transformed itself from a cardiovascular powerhouse into one of the most dominant players in modern oncolog...
Episode 51: ImmunoGen
In this episode of Petri Dish Perspectives: Biotech Unleashed, we dive into the 40+ year journey of ImmunoGen, a company that refused to give up on one of the most complex and misunderstood technologies in oncology: antibody-drug conju...
Episode 50: Exact Sciences
In this episode of Petri Dish Perspectives, we’re dissecting the "Phoenix of Biotech." On March 23, 2026, the era of Exact Sciences as an independent company officially ended with its massive $23 billion acquisition by Abbott Laboratories. But ...
Episode 49: AI in Pharma / Biotech
In this episode, we explore the high-stakes reality of AI integration in the life sciences. We move past the speculative hype to examine the mechanical necessity of this shift, driven by soaring R&D costs and an explosion of biological data...
March 2026: Biotech & Pharma NEWS Roundup
Welcome to your essential overview of the global biotech and pharmaceutical landscape for March 2026!This month was dominated by by three massive themes: more AI integrations, M&A deals, and continued GLP-1 challenges.🎧 Lis...
Episode 48: Ginkgo Bioworks
In this episode of Petri Dish Perspectives, we unpack how Ginkgo Bioworks set out to industrialize biology. From its origins at MIT to building one of the most ambitious synthetic biology platforms in the world, we explore how the comp...
Episode 47: SUN Pharma
From a small operation built on just ₹10,000 to a global pharmaceutical powerhouse, Sun Pharmaceutical Industries is one of the most compelling growth stories in modern biotech.In this episode of Petri Dish Perspectives: Biote...
Episode 46: Servier
In this episode of Petri Dish Perspectives, we explore the remarkable history of Servier, France’s largest independent pharmaceutical company and one of the only major drugmakers owned by a non-profit foundation. Founded in 1954 by the...
Episode 45: BioMarin
Most biotech companies chase massive markets. But BioMarin Pharmaceutical built its entire strategy around something very different: ultra-rare genetic diseases affecting only small patient populations around the world.In this epi...
February 2026: Biotech & Pharma NEWS Roundup
Welcome to your essential overview of the global biotech and pharmaceutical landscape for February 2026!This month was dominated by by three massive themes: The Great IPO Thaw, the "AI Factory" Era, and Regulatory Hardball.🎧 Li...
Episode 44: BioNTech
Before the world knew the power of mRNA vaccines, BioNTech was a relatively quiet biotech company focused on one ambitious goal: curing cancer through the immune system. Then the COVID-19 pandemic changed everything.In this episod...
Episode 43: ARCH Venture Partners
In this episode of Petri Dish Perspectives, we unpack the strategy and scientific conviction behind ARCH Venture Partners, the venture firm that has quietly helped build some of the most transformative companies in modern biotec...
Episode 42: Otsuka
In this episode of Petri Dish Perspectives, we explore the fascinating evolution of Otsuka Holdings, a company that defies traditional pharmaceutical stereotypes. From its origins in Japan as a chemical and nutrition-focused busin...
Episode 41: Gene Therapies
What if medicine could fix disease at its source… by rewriting the genetic code itself?In this episode of Petri Dish Perspectives, we dive into the incredible story of gene therapy, one of the most ambitious and transform...
January 2026: Biotech & Pharma NEWS Roundup
Welcome to your essential overview of the global biotech and pharmaceutical landscape for January 2026!This month was dominated by a surge in Eli Lilly's deals, partnerships, etc. 🎧 Listen now, stay curious, and don’t forg...
Episode 40: Eisai
What does it take to spend decades chasing one of medicine’s hardest problems while the rest of the industry walks away?In this episode, we explore the remarkable story of Eisai, the Japanese pharmaceutical company that built its ...
Episode 39: Flagship Pioneering
Flagship Pioneering doesn’t wait for scientific breakthroughs. It builds them. In this episode, we dive deep into the origin story of one of the most influential venture creation firms in biotech and the mind behind it, Noubar Afeyan. From his ...
Episode 38: Biogen
Biogen is one of the most influential and controversial companies in modern biotechnology. Founded in the late 1970s by Nobel-level scientists who believed recombinant DNA would redefine medicine, Biogen helped turn neurology into a commercial ...
Episode 37: Theranos
Theranos promised to revolutionize healthcare with a single drop of blood and became one of the most infamous failures in biotech history. In this episode, we trace the full rise and fall of Elizabeth Holmes and Theranos, from its f...